In Vivo Efficacy Study

  • LIDE provides diversified in vivo efficacy platforms to supporting clients’ projects. Cell-derived xenografts (CDXs) and patient-derived xenografts (PDXs) are widely applied to evaluate in vivo efficacy of indicated test article(s), with PDXs are much more relevant (~89%) to clinical translational response in compared with CDXs (only ~5%). MiniPDX, a novel platform of fast turnaround in vivo drug sensitivity test, are utilized for potential indication(s) or PDX models selection as a screening cascade. HuPBMC reconstituted or co-inoculated (with commercialized cell line or PDX cell suspension) models established in CDXs or PDXs could be ideal platforms for immunotherapies determination.
  • For detailed information, just stay tuned!